Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
4.2
Journals
Microorganisms
Special Issues
Nanoparticle-Based Vaccines and Therapeutics for Multidrug-Resistant Pathogens
share announcement

Nanoparticle-Based Vaccines and Therapeutics for Multidrug-Resistant Pathogens

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Antimicrobial Agents and Resistance".

Deadline for manuscript submissions: 15 June 2026 | Viewed by 1138

Special Issue Editors

Prof. Dr. Victor Nizet

E-Mail Website
Guest Editor
Department of Pediatrics, UC San Diego, La Jolla, CA 92093, USA
Interests: antibiotic resistance; innate immunity; multidrug-resistant pathogens
Special Issues, Collections and Topics in MDPI journals
Dr. Elisabet Bjånes

E-Mail Website
Guest Editor
Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, USA
Interests: multidrug-resistant pathogens

Special Issue Information

Dear Colleagues,

In this Special Issue, we highlight the impact that nanoparticle-based vaccines and therapeutics can play in the fight against multidrug-resistant pathogens. As the spread of antimicrobial resistance continues to reduce the available pool of effective therapeutics, the development of novel strategies is essential to prevent infection and overcome existing resistance reservoirs. The intersection of nanotechnology and medicine, creating nanotherapeutics, offers enormous promise in terms of solving the challenges faced when overcoming MDR pathogens. For example, nanovaccines and nanotherapeutics can be synthesized to optimize uptake by a desired immune cell population or tailored to enhance biodistribution. By harnessing the benefits conferred by nanotechnology into new vaccine and therapeutic applications, we unlock new mechanistic insights that can aid rational drug design and improve clinical options. This Special Issue discusses how the intersection of nanotechnology, vaccines, and therapeutics advances the frontier in terms of identifying and developing novel solutions to the multidrug resistance crisis.

As a guest editor, I invite you to submit research articles, review articles, and short communications related to nanoparticle-based vaccines and therapeutics in the context of multidrug-resistant infections.

Prof. Dr. Victor Nizet
Dr. Elisabet Bjånes
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobial resistance
  • nanotherapeutic
  • nanovaccine
  • nanomedicine
  • pathogen
  • multidrug resistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 1694 KB  
Article
Antibodies to Burkholderia pseudomallei Outer Membrane Proteins Coupled to Nanovaccines Exhibit Cross-Reactivity to B. cepacia Complex and Pseudomonas aeruginosa Homologues
by Alexander J. Badten, Susana Oaxaca-Torres and Alfredo G. Torres
Microorganisms 2026, 14(1), 221; https://doi.org/10.3390/microorganisms14010221 - 17 Jan 2026
Viewed by 884
Abstract
Burkholderia pseudomallei complex and B. cepacia complex are two evolutionary distinct clades of pathogens causing human disease. Most vaccine efforts have focused on the former group largely due to their biothreat status and global disease burden. It has been proposed that a vaccine [...] Read more.
Burkholderia pseudomallei complex and B. cepacia complex are two evolutionary distinct clades of pathogens causing human disease. Most vaccine efforts have focused on the former group largely due to their biothreat status and global disease burden. It has been proposed that a vaccine could be developed that simultaneously protects against both groups of Burkholderia by specifically targeting conserved antigens. Only a few studies have set out to identify which antigens may be optimal targets for such a vaccine. We have previously assessed the ability of three highly conserved B. pseudomallei antigens, namely OmpA1, OmpA2, and Pal, coupled to gold nanoparticle vaccines, to protect mice against a homotypic B. pseudomallei challenge. Here, we have expanded our study by demonstrating that antibodies to each of these proteins show varying levels of reactivity to homologues in B. cepacia complex, with OmpA2 antibodies exhibiting the highest cross-reactivity. Remarkably, some nanovaccine immunized mice, particularly those that received OmpA2, produced antibodies that bind Pseudomonas aeruginosa, which harbors distantly related homologous proteins. T cells elicited to Pal and OmpA2 responded to stimulation with B. cepacia complex-derived homologues. Our study supports incorporation of these antigens, particularly OmpA2, for the development of a pan-Burkholderia vaccine. Full article
(This article belongs to the Special Issue Nanoparticle-Based Vaccines and Therapeutics for Multidrug-Resistant Pathogens)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop